Daina Graybosch
Stock Analyst at Leerink Partners
(1.32)
# 3,646
Out of 5,154 analysts
99
Total ratings
42.65%
Success rate
-6.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Market Perform | $115 | $114.33 | +0.59% | 6 | Feb 24, 2026 | |
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $2.56 | -21.88% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.63 | +22.53% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.53 | +277.36% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $2.84 | +146.48% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $15.11 | -20.58% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $115.79 | +2.77% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $4.30 | +365.12% | 8 | May 15, 2024 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $70.70 | -36.35% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.33 | +651.88% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $22.11 | +71.87% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $5.00 | +59.85% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $101.50 | +120.69% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.50 | +1,100.00% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.63 | +2,590.30% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.08 | +332.69% | 4 | Feb 25, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Market Perform
Price Target: $115
Current: $114.33
Upside: +0.59%
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $2.56
Upside: -21.88%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.63
Upside: +22.53%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.53
Upside: +277.36%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $2.84
Upside: +146.48%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $15.11
Upside: -20.58%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $115.79
Upside: +2.77%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $4.30
Upside: +365.12%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $70.70
Upside: -36.35%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.33
Upside: +651.88%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $22.11
Upside: +71.87%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $5.00
Upside: +59.85%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $101.50
Upside: +120.69%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.50
Upside: +1,100.00%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.63
Upside: +2,590.30%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.08
Upside: +332.69%